1.	Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-HIC-11491, Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
2.	Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: 2003-2917, KWF 2003-2917, NCT00243529
3.	Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000335055, U10CA021115, ECOG-E1602, E1602, NCT00071981